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Abstract
Background: The posttraumatic response to traumatic brain injury (TBI) is characterized, in part,
by activation of the innate immune response, including the complement system. We have recently
shown that mice devoid of a functional alternative pathway of complement activation (factor B-/-
mice) are protected from complement-mediated neuroinflammation and neuropathology after TBI.
In the present study, we extrapolated this knowledge from studies in genetically engineered mice
to a pharmacological approach using a monoclonal anti-factor B antibody. This neutralizing antibody
represents a specific and potent inhibitor of the alternative complement pathway in mice.
Methods: A focal trauma was applied to the left hemisphere of C57BL/6 mice (n = 89) using a
standardized electric weight-drop model. Animals were randomly assigned to two treatment
groups: (1) Systemic injection of 1 mg monoclonal anti-factor B antibody (mAb 1379) in 400 µl
phosphate-buffered saline (PBS) at 1 hour and 24 hours after trauma; (2) Systemic injection of
vehicle only (400 µl PBS), as placebo control, at identical time-points after trauma. Sham-operated
and untreated mice served as additional negative controls. Evaluation of neurological scores and
analysis of brain tissue specimens and serum samples was performed at defined time-points for up
to 1 week. Complement activation in serum was assessed by zymosan assay and by murine C5a
ELISA. Brain samples were analyzed by immunohistochemistry, terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) histochemistry, and real-time RT-PCR.
Results: The mAb 1379 leads to a significant inhibition of alternative pathway complement activity
and to significantly attenuated C5a levels in serum, as compared to head-injured placebo-treated
control mice. TBI induced histomorphological signs of neuroinflammation and neuronal apoptosis
in the injured brain hemisphere of placebo-treated control mice for up to 7 days. In contrast, the
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systemic administration of an inhibitory anti-factor B antibody led to a substantial attenuation of
cerebral tissue damage and neuronal cell death. In addition, the posttraumatic administration of the
mAb 1379 induced a neuroprotective pattern of intracerebral gene expression.
Conclusion: Inhibition of the alternative complement pathway by posttraumatic administration of
a neutralizing anti-factor B antibody appears to represent a new promising avenue for
pharmacological attenuation of the complement-mediated neuroinflammatory response after head
injury.
Background
Traumatic brain injury (TBI) represents a neuroinflamma-
tory disease which is in large part mediated by an early
activation of the innate immune system [1-4]. In this
regard, the complement system has been identified as an
important early mediator of posttraumatic neuroinflam-
mation [5-7]. Research strategies to prevent the neuroin-
flammatory pathological sequelae of TBI have largely
failed in translation to clinical treatment [8-14]. This
notion is exemplified by the recent failure of the "CRASH"
trial (Corticosteroid randomization after significant head
injury). This large-scale multicenter, placebo-controlled
randomized study was designed to assess the effect of
attenuating the neuroinflammatory response after TBI by
administration of high-dose methylprednisolone [15].
The trial was unexpectedly aborted after enrollment of
10,008 patients based on the finding of a significantly
increased mortality in the steroid cohort, compared to the
placebo control group [15]. These data imply that the
"pan"-inhibition of the immune response by the use of
glucocorticoids represents a too broad and unspecific
approach for controlling neuroinflammation after TBI
[16]. Thus, research efforts are currently focusing on more
specific and sophisticated therapeutic modalities, such as
the inhibition of the complement cascade [17-19]. Several
complement inhibitors have been investigated in experi-
mental TBI models [20-26]. However, most modalities of
complement inhibition have focussed on interfering with
the cascade at the central level of the C3 convertases,
where the three activation pathways merge (Fig. 1)
[20,21,25-27]. Other approaches were designed to inhibit
the main inflammatory mediators of the complement cas-
cade, such as the anaphylatoxin C5a [22,28-30]. Only
more recently, increased attention was drawn to the "key"
role of the alternative pathway in the pathophysiology of
different inflammatory conditions outside the central
nervous system (CNS) [31-34]. We have recently reported
that factor B knockout (fB-/-) mice, which are devoid of a
functional alternative pathway, show a significant neuro-
protection after TBI, compared to head-injured wild-type
mice [35]. These data served as a baseline for the present
study, where we extrapolated the positive findings in the
knockout mice to a pharmacological approach. We there-
fore used a neutralizing monoclonal anti-factor B anti-
body which was recently described as a highly potent
inhibitor of the alternative pathway in mice [31,34,36,37]
in the setting of a standardized model of closed head
injury [38].
Methods
Animals
All experiments were performed in adult male mice of the
C57BL/6 strain (n = 89 in total) purchased from Jackson
Laboratory (Bar Harbor, ME). The mice were bred in a
selective pathogen-free (SPF) environment and under
standardized conditions of temperature (21°C), humidity
(60%), light and dark cycles (12:12 h), with food and
water provided ad libitum. Experiments were performed in
compliance with the standards of the Federation of Euro-
pean Laboratory Animal Science Association (FELASA) and
were approved by the institutional animal care committee
(Landesamt für Arbeitsschutz, Gesundheitsschutz und tech-
nische Sicherheit Berlin, Berlin, Germany, No. G0099/03).
Trauma model
Mice were subjected to experimental TBI using a standard-
ized weight-drop device, as previously described
[26,35,39,40]. In brief, after induction of isoflurane
anesthesia, the skull was exposed by a midline longitudi-
nal scalp incision. The head was fixed and a 250 g weight
was dropped on the skull from a height of 2 cm, resulting
in a focal blunt injury to the left hemisphere. After trauma,
the mice received supporting oxygenation with 100% O2
until fully awake. The extent of posttraumatic neurologi-
cal impairment was assessed at defined time intervals after
trauma (t = 1 h, 4 h, 24 h, and 7 days) using a standard-
ized Neurological Severity Score (NSS), as described below.
Treatment protocol
The inhibitory monoclonal anti-factor B antibody (mAb
1379) used in this study was previously described and the
selected dosage was in the titrated range used in other
studies on murine models of inflammation [34,36,37].
The antibody itself does not have any complement-acti-
vating properties. Mice were randomly assigned to two
treatment groups: (1) Systemic injection of 1 mg mAb
1379 in 400 µl phosphate-buffered saline (PBS) at 1 hour
and 24 hours after trauma; (2) Systemic injection of vehi-
cle only (400 µl PBS), as placebo control, at identical
time-points after trauma. Concealed allocation to the twoJournal of Neuroinflammation 2007, 4:13 http://www.jneuroinflammation.com/content/4/1/13
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Schematic drawing of complement activation pathways, immunological functions, and specific inhibitory strategies used in  experimental head injury models Figure 1
Schematic drawing of complement activation pathways, immunological functions, and specific inhibitory strat-
egies used in experimental head injury models. Complement is activated either through the classical, lectin, or alterna-
tive pathways. Activation of complement leads to the formation of multi-molecular enzyme complexes termed convertases 
that cleave C3 and C5, the central proteins of the complement system. The proteolytic fragments generated by cleavage of C3 
and C5 mediate most of the biological activities of complement. C3b, and proteolytic fragments generated from C3b, are 
important opsonins that target pathogens for removal by phagocytic cells via complement receptors specific for these proteins. 
These molecules have furthermore been shown to bridge innate to adaptive immune responses by the activation of B-cells. 
C3a and C5a are potent anaphylatoxins with chemotactic and inflammatory properties. Generation of C5b by cleavage of C5 
initiates the formation of the membrane attack complex (MAC, C5b-9) through the terminal complement pathway. The MAC 
forms through the self-association of C5b along with C6 through C9 and leads to the formation of a large membranolytic com-
plex capable of lysing cells. Therapeutic modalities from experimental head injury models are aimed either at blocking specific 
activation pathways (classical, alternative), components (C5) and proteolytic fragments (C5a, C5aR), or by a "pan"-inhibition of 
C3 convertases, leading to a complete shut-down of complement activation. See text for references and explanations. C1-Inh, C1-
inhibitor; C5aR, anaphylatoxin C5a receptor (CD88); Crry-Ig, Complement receptor type 1-related protein y, IgG1-linked 
murine recombinant fusion protein; MBP, mannose-binding protein; rVCP, recombinant Vaccinia virus complement control 
protein; sCR1, soluble complement receptor type 1.
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treatment cohorts was performed after assessment of the
baseline NSS at 1 hour after trauma, in order to ensure
equal injury severity between the groups. The systemic
(i.p.) route of administration and the time window of
injection were selected based on the breakdown of the
blood-brain barrier (BBB) for up to 24 hours after trauma
[38,41]. This allows a "time window" for peripherally
administered compounds to reach the intrathecal com-
partment and exert pharmacological effects in the CNS
[26,39,40,42]. Furthermore, the systemic injection early
after trauma represents an approach with potential clini-
cal implications. In order to induce a continuing comple-
ment inhibition during the acute inflammatory phase in
the first days, injections were repeated at 24 hours.
Subgroups of mice (n = 10 per group and time-point)
were euthanized by isoflurane anesthesia and decapitated
at t = 4 h, 24 h, and 7 days. Brains were immediately
extracted, snap-frozen in liquid nitrogen and stored at -
80°C until analysis by immunohistochemistry, TUNEL
histochemistry and real-time RT-PCR. In addition, serum
samples were collected at identical time-points for deter-
mination of complement activation levels. Sham-oper-
ated and untreated normal mice served as negative
controls.
Neurological Severity Score (NSS)
A previously characterized 10-parameter score was used
for assessment of posttraumatic neurological impairment,
as described elsewhere in detail [41,43]. The NSS was
assessed in a blinded fashion by two different investiga-
tors at the time-points t = 1 h, 4 h, 24 h, and 7 days after
trauma. The score comprises 10 individual parameters,
including tasks on motor function, alertness, and physio-
logical behavior, whereby one point is given for failure of
the task, and no point for succeeding. A maximum NSS
score of 10 points indicates severe neurological dysfunc-
tion, with failure of all tasks.
Mouse C5a ELISA
Serum levels of the complement anaphylatoxin C5a were
determined by a mouse-specific ELISA developed in the
laboratory of Dr. P.A. Ward (Ann Arbor, MI), as previ-
ously described [35,44]. In brief, ELISA plates (Immulon
4HBX, Thermo Labsystems, Milford, MA) were coated
with 5 µg/ml of purified monoclonal anti-mouse C5a IgG
(BD Pharmingen, San Diego, CA). After blocking of non-
specific binding sites with 1% milk (Roth, Karlsruhe, Ger-
many) in PBS (Gibco-Invitrogen, Carlsbad, CA) contain-
ing 0.05% TWEEN 20 (Sigma-Aldrich), the plate was
coated with 100 µl of each serum diluted 1:20 (in 0.1%
milk in PBS containing 0.05% TWEEN) and murine
recombinant mouse C5a at defined concentrations for
establishing the standard curve. After incubation and sub-
sequent washing steps, biotinylated monoclonal anti-
mouse C5a antibody was added at 500 ng/ml (BD
Pharmingen) followed by washing steps and incubation
with streptavidin-peroxidase at 400 ng/ml (Sigma-
Aldrich).
For colorimetric reaction, 0.4 mg/ml o-phenylenediamine
dihydrochloride with 0.4 mg/ml urea hydrogen peroxide
in 0.05 M phosphate citrate buffer (Sigma-Aldrich) was
added and the color reaction was stopped with 3 M sulfu-
ric acid. Absorbance was read at 490 nm using a "Spec-
traMax 190" reader (Molecular Devices, Sunnyvale, CA).
All samples were analyzed in duplicate and results were
calculated from the means of duplicate sample analysis.
The standard curve was linear from 0.1 ng/ml to 50 ng/ml.
Quantification of alternative pathway complement 
activity
Alternative pathway complement activity in mouse serum
was quantified as previously described [26,36]. Briefly, at
the above-mentioned defined time-points, whole blood
was collected and spun down, serum was aliquoted and
stored at -80°C until analyzed. Ten microlitres of serum
from each animal was incubated with 109 zymosan parti-
cles (Sigma-Aldrich, St. Louis, MO) at 37°C for 30 min in
a master mix containing final concentrations of 5 mM
MgCl2 and 10 mM EGTA and brought up to 100 µl in cal-
cium-free PBS. C3 deposition on the particles was
detected with a FITC-labeled antibody to C3 (Cappel,
Durham, USA) diluted 1:100 and fluorescence was meas-
ured by flow cytometry. Complement activity was calcu-
lated using the formula:
Immunohistochemistry
Immunohistochemical stainings of serial coronal cryosec-
tions (8 µm) of brain tissue were performed using a
biotin/avidin/peroxidase technique with diaminobenzi-
dine tetrahydrochloride as chromogen (Vector, Burlin-
game, CA). The following primary antibodies were used as
cell-markers: monoclonal anti-NeuN for neurons
(1:2,000; Chemicon, Hampshire, UK); polyclonal rabbit
anti-GFAP for astrocytes (1:100; Shandon Immunon,
Pittsburgh, PA) and monoclonal rat anti-CD11b for
microglia and monocytes/macrophages (1:100; Accurate
Chemical, Westbury, NY). For negative control, non-
immunized IgG (Vector) was used at equal dilutions.
TUNEL assay
The terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) technique was applied to determine the
extent of neuronal cell death in tissue sections. Herefore,
the commercially available ''Fluorescein In Situ Cell Death
Detection Kit'' (Roche Diagnostics GmbH, Mannheim,
100×
− ([ sample mean channel fluorescence background no serum         ] ])
() positive control mean channel fluorescence background        −Journal of Neuroinflammation 2007, 4:13 http://www.jneuroinflammation.com/content/4/1/13
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Germany) was used according to the manufacturer's
instructions, as previously described [35]. In brief, slides
were dried for 30 min followed by fixation in 10% forma-
lin solution at RT. After washing in PBS, sections were
incubated in ice-cold ethanol-acetic acid solution (3:1),
washed in PBS and incubated with 3% Triton X-100 solu-
tion for 60 min at RT for permeabilization. Slides were
then incubated with the TdT-enzyme in reaction buffer
containing fluorescein-dUTP for 90 min at 37°C. Nega-
tive control was performed using only the reaction buffer
without TdT enzyme. Positive controls were performed by
digesting with 500 U/ml DNase grade I solution (Roche).
To preserve cells for comparison, slices were covered with
Vectashield®  mounting medium containing 4',6'-
diamino-2-phenylindole (DAPI; Vector). All samples
were evaluated immediately after staining using an ''Axi-
oskop 40'' fluorescence microscope (Zeiss, Germany) at
460 nm for DAPI and 520 nm for TUNEL fluorescence.
Data were analyzed by Alpha digi doc 1201 software
(Alpha Innotech, San Leandro, CA).
Real-time RT-PCR
Changes in the expression profiles of pro- and anti-apop-
totic as well as complement-regulatory genes were deter-
mined by semi-quantitative two-step real-time RT-PCR
using commercially available and custom-made murine-
specific primers shown in table 1. This technique was pre-
viously described [26]. In brief, brains were homogenized
per hemisphere in Qiazol® buffer (Qiagen, Hilden, Ger-
many). RNA was isolated and further purified using RNe-
asy®  Mini-kits (Qiagen) and RNA concentrations were
measured using a spectrophotometer (Bio-Rad, Munich,
Germany). From each brain hemisphere, 2 µg RNA were
reversed transcribed using random nonamer and oligo-
dT16mer primers (Operon Biotechnologies, Cologne,
Germany) with Omniscript® kits (Qiagen), according to
the manufacturer's instructions. Real-time RT-PCR was
performed using validated commercially available and
custom designed primer-probe® sets (Qiagen) and opti-
mized protocols on the Opticon® real-time PCR Detection
System (Bio-Rad). For quantification of gene expression
levels, GAPDH amplicons were generated and used as a
house-keeping internal control gene. Relative gene expres-
sion levels were calculated in relation to the correspond-
ing GAPDH gene expression levels.
Statistical analysis
Statistical analysis was performed using commercially
available software (SPSS 9.0 for Windows™). Differences
in serum complement activity levels and in intracerebral
gene expression levels between the groups were deter-
mined by the unpaired Student's t-test. The repeated
measures analysis of variance (ANOVA) was used for
assessing differences in neurological scores (NSS). A P-
value < 0.05 was considered statistically significant.
Results
mAb 1379 inhibits complement activation after TBI
The induction of TBI lead to a significant extent of sys-
temic complement activation within 4 hours after trauma,
as revealed by significantly increased anaphylatoxin C5a
serum levels (P < 0.05 vs. control, unpaired Student's t-
test; Fig. 2). Peak C5a levels at 4 h after head injury were
as high as 450 ng/ml, compared to 42–53 ng/ml in con-
trols. C5a levels in serum remained significantly elevated
for up to 7 days after head injury (Fig. 2). In contrast, the
systemic (i.p.) injection of 1 mg mAb 1379 at one hour
post trauma lead to a significant reduction of anaphyla-
toxin C5a levels in serum at 4 h and 24 h after head injury.
The mean C5a levels (± SD) were reduced from 361 ± 59
ng/ml (TBI 4 h) and 333 ± 29 ng/ml (TBI 24 h) in the pla-
cebo group to 111 ± 36 ng/ml (TBI 4 h) and 118 ± 30 ng/
ml (TBI 24 h) in the mAb 1379 group (P < 0.05, unpaired
Student's t-test; Fig. 2). However, a repeated injection of
mAb 1379 at 24 hours did not mediate a prolonged inhi-
bition of C5a levels for up to 7 days after trauma (316 ±
37 ng/ml in the placebo group vs. 265 ± 51 ng/ml in the
mAb 1379 group, P > 0.05; Fig. 2). Similarly to the reduced
C5a levels, the mAb 1379 led to a significant reduction of
alternative pathway complement activity in serum at 4 h
and 24 h after TBI, as assessed by zymosan assay (P < 0.05
vs. PBS-injected TBI mice, unpaired Student's t-test; Fig. 3).
The repeated injection of mAb 1379 at 24 hours could not
maintain the alternative pathway inhibition for up to 7
Table 1: Murine primer sequences used for real-time RT-PCR analysis of intracerebral gene expression
Gene ID at 
NCBI *
GeneBank 
Accession No.
Length of 
amplicons
Primer sequence Probe Sequence Order No. 
Qiagen
GAPDH# 14433 NM_008084 136 bp commercially available Genexpression Assay QuantiTect Mm_GAPD 241012
Bcl-2 12043 NM_009741
NM_177410
118 bp commercially available Genexpression Assay QuantiTect Mm_Bcl-2 241118
Fas 14102 NM_007987 96 bp commercially available Genexpression Assay QuantiTect Mm_ Tnfsf6 241122
C1-Inh 12258 NM_009776 134 bp AACTTAGAACTCATCAACACCT
GTTATCTTCCACTTGGCACTC
ACACCTGCCTCGTCCT custom 
made
* NCBI, National Center for Biotechnology Information
# Housekeeping geneJournal of Neuroinflammation 2007, 4:13 http://www.jneuroinflammation.com/content/4/1/13
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days after trauma (P > 0.05 vs. PBS-injected TBI mice; Fig.
3).
Clinical outcome
Evaluation of neurological tasks was performed by two
investigators who were blinded about the treatment
groups. The mortality from brain injury in this model was
below 10% within 7 days, as previously reported [41]. No
difference in mortality was observed between head-
injured mice in the placebo vs. the mAb 1379 injected
group (data not shown). With regard to the neurological
outcome, the 'nil' and sham control mice showed a nor-
mal behavior, as reflected by low mean NSS scores of 0 to
0.67 points (range:0–2 points). In contrast, head-injured
mice in both treatment groups had a significantly
increased NSS at all time-points assessed for up to 7 days
after trauma, compared to the control groups (P < 0.05,
repeated measures ANOVA; Fig. 4). No significant differ-
ences in neurological scores were observed between the
groups treated with vehicle vs. the mAb 1379, as shown in
Fig. 4. A spontaneous neurological recovery was seen in
both treatment groups over time, as reflected by a
decreased NSS at 7 days (vehicle: 2.40 ± 0.52, mean ± SD;
mAb 1379: 2.30 ± 0.30) compared to 1 hour after TBI
(vehicle: 5.67 ± 0.33; mAb 1379: 5.27 ± 0.31).
Both treatment groups had a weight loss of approximately
10% of their initial body weight within 24 h after trauma,
and regained their baseline values by 7 days. No signifi-
cant differences in body weight were observed between
the vehicle and mAb 1379 groups (Fig. 5).
Histomorphological outcome
Morphologically, the placebo-injected mice exhibited a
massive destruction of their cortical neuronal layers for up
to 7 days after trauma, as determined by immunohisto-
chemistry using a specific anti-NeuN Ab as a neuronal
marker (Fig. 6B). In contrast, the mAb 1379-injected mice
showed signs of neuronal protection and restoration of
the cortical layers to a similar anatomy as in sham-oper-
ated mice (Fig. 6A,C). A similar extent of neuroprotection
in mAb 1379-treated mice was seen in the CA3/CA4 sub-
layers of the hippocampus, compared to placebo-treated
mice (data not shown). The staining of brain tissue sec-
tion using an anti-CD11b Ab revealed infiltration of
CD11b-positive inflammatory cells at the contusion site
of brain-injured mice in the placebo group, but not in the
mAb 1379 group (Fig. 6E,F).
Functional assessment of mAb 1379 on alternative comple- ment pathway activity after traumatic brain injury (TBI) Figure 3
Functional assessment of mAb 1379 on alternative 
complement pathway activity after traumatic brain 
injury (TBI). Relative alternative pathway complement 
activity levels (normalized to 100%) were determined by 
zymosan assay in murine serum samples, as described in the 
methods section. The mAb 1379-injected mice showed a sig-
nificant decrease in alternative complement activity com-
pared to placebo-injected mice at 4 hours and 24 hours, but 
not at 7 days after TBI. Data are shown as mean levels ± SD 
of n = 5 animals per group and time-point. *P < 0.05, for 
TBI_mAb 1379 (4 h) and TBI_mAb 1379 (24 h) vs. 
TBI_placebo and sham; unpaired Student's t-test.
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Posttraumatic injection of mAb 1379 attenuates C5a levels in  serum of head-injured mice Figure 2
Posttraumatic injection of mAb 1379 attenuates C5a 
levels in serum of head-injured mice. Serum samples 
from mice treated with placebo or mAb1379 were analyzed 
by a specific murine C5a ELISA, as described in the methods 
section. C5a levels were significantly decreased in mAb1379-
treated mice compared to placebo controls at 4 and 24 
hours (P < 0.05, unpaired Student's t-test), but not at 7 days 
after trauma (n.s., not significant). Data are shown as mean 
levels ± SD of n = 3 animals per group and time-point. *P < 
0.05 head-injured placebo-injected mice vs. normal controls 
(unpaired Student's t-test). TBI, traumatic brain injury.
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The assessment of intracerebral cell death by TUNEL his-
tochemistry revealed a dramatic increase in TUNEL-posi-
tive neurons in the injured left hemispheres of PBS-
injected mice at 4 hours after trauma, as previously
described for this TBI model [35]. TUNEL-positive cells
were detected within the contused area (Fig. 6L) and the
hippocampus (not shown) of the injured hemisphere for
for up to 7 days after trauma, as compared to sham-oper-
ated animals (Fig. 6K). In contrast, the mAb 1379 treated
mice showed a clearly attenuated extent of intracerebral
cell death in the ipsilateral hippocampus (not shown) and
cortex around the contusion zone for up to 7 days after
trauma (Fig. 6M). Immunohistochemical staining of adja-
cent sections to those analyzed by TUNEL histochemistry
by cell markers for neurons (anti-NeuN), astrocytes (anti-
GFAP), and microglia and infiltrating leukocytes (anti-
CD11b), revealed that neurons were the predominant
TUNEL-positive cell type in all sections taken from the
injured hemisphere in PBS-treated mice. Neurons were
also confirmed as the predominant TUNEL-positive cell-
type by their typical cellular size, morphology, and posi-
tion in typical neuronal layers. In addition, some infiltrat-
ing leukocytes within the contusion site were shown to be
TUNEL-positive at the time-point of 7 days after trauma
(Fig. 6L). TUNEL-positive cells and the extent of cortical
tissue destruction were less apparent in the contralateral
(right) hemisphere as compared to the injured (left) hem-
isphere at all time-points assessed after trauma (data not
shown). The representative microphotographs shown in
Fig. 6 were highly reproducible in all tissue sections and
animals assessed.
Intracerebral gene regulation
Expression of intracerebral genes of interest was assessed
by semi-quantitative real-time RT-PCR analysis of brain
tissue homogenates using mouse-specific primers (table
1). These included each a pro-apoptotic (Fas) and anti-
apoptotic (Bcl-2) gene and a representative complement
regulatory gene of the classical pathway (Inh). The base-
line expression of these candidate genes was determined
in brain homogenates from untreated normal mice („nil“
group, n = 3 per gene, Fig. 7). Sham-operated control mice
(n = 6 per gene and time-point) showed a non-significant
increase in the expression of Bcl-2, C1-Inh, and Fas at each
time point assessed („sham“ group, n = 6 per gene and
time-point, Fig. 7).
After head trauma, the mAb1379-injected mice showed a
significant upregulation of the protective Bcl-2 and C1-
Inh genes for up to 7 days, as compared to placebo-
injected or sham-operated mice (P < 0.05, unpaired Stu-
dent's t-test; n = 6 per gene, time-point, and TBI group Fig.
Kinetics of body weight changes for up to 7 days after trau- matic brain injury (TBI) Figure 5
Kinetics of body weight changes for up to 7 days after 
traumatic brain injury (TBI). Both TBI groups had a 
decrease in body weight at 24 hours after trauma, compared 
to baseline values. No significant changes were seen between 
the mAb 1379- vs. placebo-injected groups (P > 0.05, 
repeated measures ANOVA). Head-injured mice recovered 
their baseline body weight by 7 days. Median values are 
shown for a total of n = 89 mice.
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Neurological outcome after head injury is not altered by  injection of mAb 1379 Figure 4
Neurological outcome after head injury is not altered 
by injection of mAb 1379. The extent of neurological 
impairment was assessed using a standardized 10-parameter 
"Neurological Severity Score" (NSS) in normal, sham-operated, 
and head-injured mice from 1 hour to 7 days after trauma 
(total: n = 89 mice). Neurological assessment was performed 
by two investigators in a blinded fashion. A maximal score of 
10 points corresponds to a severe neurological impairment, 
while a score of 0 points reflects normal behavior [41,43]. 
The graph shows median levels of the groups at different 
time-points. No statistically significant differences where 
found at any time-point between head-injured mice treated 
with either mAb 1379 or placebo (P > 0.05, repeated meas-
ures ANOVA). TBI, traumatic brain injury.
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Neuroprotection at the brain tissue level by mAb1379 treatment of head-injured mice Figure 6
Neuroprotection at the brain tissue level by mAb1379 treatment of head-injured mice. Adjacent cryosections of 6–
8 µm thickness are shown for sham-operated (panels A, D, H, K) and head-injured mice treated by placebo (panels B, E, I, 
L) or mAb 1379 (panels C, F, J, M) at the time-point of 7 days. Immunohistochemical staining by the use of a neuron-specific 
marker (NeuN, panels A-C) shows a significant tissue destruction of the cortical neuronal layers of the injured hemisphere in 
placebo-injected mice (B). In contrast, the injured hemisphere appears largely protected in mAb 1379-treated mice (C), show-
ing a similarly intact neuronal cell layer morphology as in sham-operated animals (A). The staining of infiltrating leukocytes by a 
marker for complement receptor type 3 (CD11b, panels D-F) shows positive cells in the disrupted subarachnoid space of pla-
cebo-injected mice (E), but not in mAb 1379-injected animals (F). Furthermore, TUNEL-histochemistry (panels K-M) 
revealed positive cells in the injured hemisphere of placebo-injected head-injured mice (L), but not in mAb 1379-treated ani-
mals (M). The 4',6'-diamino-2-phenylindole (DAPI) stainings (panels H-J) show the overall nuclear morphology in adjacent 
sections to those stained by TUNEL. TBI, traumatic brain injury. Original magnifications: 100 ×.
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7). In contrast, Fas gene expression in injured brains
showed different kinetics of regulation, with mRNA levels
being significantly elevated in both TBI groups (placebo
and mAB 1379) as early as 4 hours after trauma, compared
to sham-operated mice (P < 0.05, unpaired Student's t-
test; n = 6 per gene, time-point, and TBI group Fig. 7). As
opposed to the Bcl-2 and C1-Inh genes, no significant dif-
ferences in Fas gene expression were seen between the
mAB 1379 and placebo-control groups at 4 hours and 7
days after trauma (Fig. 7). However, at 24 hours, Fas
mRNA levels were significantly suppressed in the treat-
ment group, reaching similar low levels as the sham con-
trols (P < 0.05, mAb1379 vs. PBS group; Fig. 7).
Discussion
Therapeutic modalities for inhibition of the complement
cascade have been assessed in different models of brain
injury in the past [5,17,23]. Most of these studies have
used pharmacological approaches which led to complete
"shut-down" of the complement system at the level where
the three different activation pathways merge by inhibit-
ing the C3 convertases (Fig. 1) [20,21,25,26]. A recent
experimental study from our laboratory suggests, how-
ever, that the alternative pathway may be of particular
importance in mediating neuroinflammation and neuro-
nal cell death after head injury, based on studies in factor
B gene knockout (fB-/-) mice [35]. The selective inhibition
Regulation of intracerebral expression of Bcl-2 (A), Fas (B), and C1-Inh (C) genes after head injury, as assessed by semi-quanti- tative two-step real-time RT-PCR Figure 7
Regulation of intracerebral expression of Bcl-2 (A), Fas (B), and C1-Inh (C) genes after head injury, as assessed 
by semi-quantitative two-step real-time RT-PCR. Total RNA was extracted from homogenized murine brains at 4 
hours, 24 hours, and 7 days after traumatic brain injury (TBI). The murine primers for GAPDH, Bcl-2, Fas and C1-Inh are 
depicted in table 1. The technique for real-time RT-PCR analysis is described in the methods section. See text for details. Data 
are shown as means ± SD of n = 3 in the "nil" group and n = 6 per time-point in all other groups. *P < 0.05 for TBI_mAb 1379 
vs. TBI_placebo groups; #P < 0.05 for TBI vs. sham groups; **P < 0.05 for TBI_placebo vs. TBI_mAb 1379 vs. placebo group 
(unpaired Student's t-test).
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of the alternative pathway only has received increasing
attention in various inflammatory diseases outside the
CNS, due to recent findings which support its essential
role in contributing to secondary tissue injury [31,32].
Based on our recent findings of a significant neuroprotec-
tion in fB-/- mice after TBI, we sought to extrapolate these
findings to a pharmacological model by targeted inhibi-
tion of the alternative pathway [35]. We therefore used a
newly available, highly specific and potent inhibitor of
the alternative complement pathway, the mAb 1379 mon-
oclonal anti-factor B antibody, in the identical head injury
model. This antibody was previously shown to protect
form inflammation and severity of disease in allergic air-
way inflammation, renal ischemia/reperfusion syndrome,
and anti-phospholipid antibody-induced pregnancy loss
in mice [34,36,37].
In the present study, we randomized adult male C57BL/6
to receive a systemic injection of either 1 mg mAb 1379 or
placebo (vehicle only) at 1 hour and 24 hours after closed
head injury. The selected dosage was in the titrated range
used in previous studies on other murine models of
inflammation [34,36,37]. The systemic (i.p.) route of
administration and the time window of injection were
selected based on the rationale that in this model system,
the blood-brain barrier is breached as early as 1 hour after
trauma, peaking at 4 hours, and persisting for up to 24
hours [38,41]. These kinetics of blood-brain barrier open-
ing offer a "time window of opportunity" for peripherally
administered compounds to reach the intrathecal com-
partment and exert pharmacological effects in the
inflamed CNS, as previously shown for other pharmaco-
logical agents [26,39,40,42]. Furthermore, the post-
trauma systemic injection within 1 to 24 hours after injury
represents an approach with potential clinical implica-
tions [10,14].
Our data demonstrate that the mAb 1379 represents a
potent complement inhibitor after TBI, based on a signif-
icant attenuation of alternative pathway complement
activity (zymosan assay) and a significant inhibition of
complement anaphylatoxin C5a levels (ELISA data) at 4
and 24 hours after trauma, compared to placebo controls.
However, while the injection of 1 mg mAb 1379 induced
a complement inhibition for up to 24 hours, the repeated
injection at this time-point was obviously not sufficient
for sustaining a prolonged inhibition of complement acti-
vation until 7 days after injury. In other experimental
models of inflammation, we have recently found that the
hepatic factor B synthesis is increased due to initiation of
the acute-phase response, thus necessitating higher doses
of mAb 1379 for complete inhibition (Holers VM, Thur-
man JM; unpublished observations).
Aside from the shortcoming of limited complement inhi-
bition related to the half-life of the compound, compen-
satory inflammatory reactions may also account for the
lack of neurological improvement. These compensatory
effects include the release of pro-inflammatory cytokines
in the injured brain, such as tumor necrosis factor (TNF)
and of interleukins (IL) -1β, -8, -12, -18, and other medi-
ators of neuroinflammation [2,45,46]. Finally, the neuro-
logical score used in the present study (NSS), albeit widely
used with success in previous studies on this model sys-
tem [26,27,39-43], may not be sensitive enough to detect
subtle changes in performance attributed to morphologi-
cal alterations of cerebral tissue damage. Thus, other neu-
rological testing systems may have to be applied in future
studies to test the relevance of this compound in neuro-
trauma in more detail, including the Morris water maze
for assessment of memory tasks.
Despite the lack of neurological improvement in the mAb
1379-treated mice, we observed an impressive extent of
neuroprotection at the tissue level and a significant induc-
tion of neuroprotective genes in the injured brain. Specif-
ically, the mAb 1379-treated mice had an attenuated
extent of neuronal cell death and a preserved cortical
microarchitecture for up to 7 days after head injury, com-
pared to placebo controls. These promising findings
imply that with a modified protocol of mAb 1379 admin-
istration, e.g. by higher doses or repeated injections every
24 hours for the first week, may lead to an increased extent
of cerebral neuroprotection which will likely influence the
outcome at a clinical-neurological level. Another strategy
could involve the use of therapies targeted to the brain
using CR2-linked chimeras which might provide more
complete local control of complement activation [47,48].
This hypothesis will have to be tested in future experimen-
tal studies.
Conclusion
The alternative pathway of complement activation
appears to play a more crucial role in the pathophysiology
of complement-mediated neuroinflammation after TBI
than previously appreciated. In the present study, we
extrapolated previous findings of neuroprotection in fac-
tor B gene-deficient (fB-/-) mice [35] to a pharmacological
approach using a specific and potent inhibitor of the alter-
native complement pathway (mAb 1379). The rand-
omized treatment protocol used in this experimental
study on closed head injury in mice revealed the following
mAb 1379-mediated beneficial effects, as compared to pla-
cebo controls:
(1)  A significant attenuation of complement pathway
activity at the level of the alternative pathway (zymosan
assay) and overall at the level of anaphylatoxin formation
(C5a ELISA).Journal of Neuroinflammation 2007, 4:13 http://www.jneuroinflammation.com/content/4/1/13
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(2)  An impressive reduction of neuronal cell death
(TUNEL) and a restoration of cortical cell layers in the
injured hemisphere (immunohistochemistry).
(3) A significant upregulation of candidate neuroprotec-
tive genes in the injured hemisphere (real-time RT-PCR).
However, these neuroprotective effects at the tissue level
did not extend to an improved neurological outcome or to
reduced mortality in mAb 1379-treated mice, as compared
to placebo controls. The observation of elevated factor B
levels in the intrathecal compartment of severely head-
injured patients further supports the pharmacological
concept of a specific inhibition of factor B [49]. However,
prior to extrapolation to the clinical setting, further ani-
mal studies will be required for determining the optimal
dosage and injection intervals in experimental models of
head injury.
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